Similar to HOXD-AS1, the STARD13 (DLC2, a RhoGAP) 3’UTR acts as a ceRNA and increases Bcl-2 modifying factor (BMF) expression by competitively binding with miR-125b in breast cancer. Here, BMF is linked to breast carcinoma.